A citation-based method for searching scientific literature

Nihal El Rouby, John J Lima, Julie A Johnson. Expert Opin Drug Metab Toxicol 2018
Times Cited: 49







List of co-cited articles
244 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants.
Sarah C Sim, Carl Risinger, Marja-Liisa Dahl, Eleni Aklillu, Magnus Christensen, Leif Bertilsson, Magnus Ingelman-Sundberg. Clin Pharmacol Ther 2006
509
18

Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.
S A Scott, K Sangkuhl, C M Stein, J-S Hulot, J L Mega, D M Roden, T E Klein, M S Sabatine, J A Johnson, A R Shuldiner. Clin Pharmacol Ther 2013
555
18

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors.
J K Hicks, J R Bishop, K Sangkuhl, D J Müller, Y Ji, S G Leckband, J S Leeder, R L Graham, D L Chiulli, A LLerena,[...]. Clin Pharmacol Ther 2015
427
18

Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report.
P Malfertheiner, F Megraud, C A O'Morain, J P Gisbert, E J Kuipers, A T Axon, F Bazzoli, A Gasbarrini, J Atherton, D Y Graham,[...]. Gut 2017
14

Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron.
G C Bell, K E Caudle, M Whirl-Carrillo, R J Gordon, K Hikino, C A Prows, A Gaedigk, Jag Agundez, S Sadhasivam, T E Klein,[...]. Clin Pharmacol Ther 2017
85
14

Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update.
J K Hicks, K Sangkuhl, J J Swen, V L Ellingrod, D J Müller, K Shimoda, J R Bishop, E D Kharasch, T C Skaar, A Gaedigk,[...]. Clin Pharmacol Ther 2017
226
14

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing.
John J Lima, Cameron D Thomas, Julia Barbarino, Zeruesenay Desta, Sara L Van Driest, Nihal El Rouby, Julie A Johnson, Larisa H Cavallari, Valentina Shakhnovich, David L Thacker,[...]. Clin Pharmacol Ther 2021
31
22

Association Between CYP2C19*17 Alleles and pH Probe Testing Outcomes in Children With Symptomatic Gastroesophageal Reflux.
James P Franciosi, Edward B Mougey, Andre Williams, Roberto A Gomez-Suarez, Cameron Thomas, Christa L Creech, Katherine George, Diana Corao, John J Lima. J Clin Pharmacol 2018
14
42

Rapid metabolizer genotype of CYP2C19 is a risk factor of being refractory to proton pump inhibitor therapy for reflux esophagitis.
Hitomi Ichikawa, Mitsushige Sugimoto, Ken Sugimoto, Akira Andoh, Takahisa Furuta. J Gastroenterol Hepatol 2016
29
20

Pharmacogenomics in the clinic.
Mary V Relling, William E Evans. Nature 2015
371
12

CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans.
T Furuta, K Ohashi, K Kosuge, X J Zhao, M Takashima, M Kimura, M Nishimoto, H Hanai, E Kaneko, T Ishizaki. Clin Pharmacol Ther 1999
240
10

Association between CYP2C19 extensive metabolizer phenotype and childhood anti-reflux surgery following failed proton pump inhibitor medication treatment.
James P Franciosi, Edward B Mougey, Andre Williams, Roberto A Gomez Suarez, Cameron Thomas, Christa L Creech, Katherine George, Diana Corao, John J Lima. Eur J Pediatr 2018
13
38

Pharmacogenetics: from bench to byte--an update of guidelines.
J J Swen, M Nijenhuis, A de Boer, L Grandia, A H Maitland-van der Zee, H Mulder, G A P J M Rongen, R H N van Schaik, T Schalekamp, D J Touw,[...]. Clin Pharmacol Ther 2011
593
10

Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype.
Hai-Ling Qiao, Yu-Rong Hu, Xin Tian, Lin-Jing Jia, Na Gao, Li-Rong Zhang, Yu-Zhong Guo. Eur J Clin Pharmacol 2006
36
13

CYP2C19 polymorphism influences Helicobacter pylori eradication.
Chao-Hung Kuo, Chien-Yu Lu, Hsiang-Yao Shih, Chung-Jung Liu, Meng-Chieh Wu, Huang-Ming Hu, Wen-Hung Hsu, Fang-Jung Yu, Deng-Chyang Wu, Fu-Chen Kuo. World J Gastroenterol 2014
50
10

ACG Clinical Guideline: Treatment of Helicobacter pylori Infection.
William D Chey, Grigorios I Leontiadis, Colin W Howden, Steven F Moss. Am J Gastroenterol 2017
490
10

Rapid and ultra-rapid metabolizers with CYP2C19*17 polymorphism do not respond to standard therapy with proton pump inhibitors.
Neha Deshpande, Sharanya V, Ravi Kanth V V, Murthy H V V, Sasikala M, Rupa Banerjee, Manu Tandan, Nageshwar Reddy D. Meta Gene 2016
17
29

Pharmacology of proton pump inhibitors.
Jai Moo Shin, George Sachs. Curr Gastroenterol Rep 2008
188
10

25 Years of Proton Pump Inhibitors: A Comprehensive Review.
Daniel S Strand, Daejin Kim, David A Peura. Gut Liver 2017
144
10

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update.
J A Johnson, K E Caudle, L Gong, M Whirl-Carrillo, C M Stein, S A Scott, M T Lee, B F Gage, S E Kimmel, M A Perera,[...]. Clin Pharmacol Ther 2017
255
10

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy.
B Moriyama, A Owusu Obeng, J Barbarino, S R Penzak, S A Henning, S A Scott, Jag Agúndez, J R Wingard, H L McLeod, T E Klein,[...]. Clin Pharmacol Ther 2017
133
10

Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update.
K R Crews, A Gaedigk, H M Dunnenberger, J S Leeder, T E Klein, K E Caudle, C E Haidar, D D Shen, J T Callaghan, S Sadhasivam,[...]. Clin Pharmacol Ther 2014
382
10

Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis.
Fujun Zhao, Jing Wang, Yanmei Yang, Xiaoyong Wang, Ruihua Shi, Zekuan Xu, Zuhu Huang, Guoxin Zhang. Helicobacter 2008
82
10

Multi-ethnic distribution of clinically relevant CYP2C genotypes and haplotypes.
S Martis, I Peter, J-S Hulot, R Kornreich, R J Desnick, S A Scott. Pharmacogenomics J 2013
61
8

Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC).
Kelly E Caudle, Henry M Dunnenberger, Robert R Freimuth, Josh F Peterson, Jonathan D Burlison, Michelle Whirl-Carrillo, Stuart A Scott, Heidi L Rehm, Marc S Williams, Teri E Klein,[...]. Genet Med 2017
226
8



Effect of CYP2C19 Gene Polymorphisms on Proton Pump Inhibitor, Amoxicillin, and Levofloxacin Triple Therapy for Eradication of Helicobacter Pylori.
Yun-An Lin, Hong Wang, Zhu-Jun Gu, Wen-Jia Wang, Xiao-Yan Zeng, Yan-Lei Du, Song-Song Ying, Bo-Hua Zhang. Med Sci Monit 2017
11
36

Limited frequency of the CYP2C19*17 allele and its minor role in a Japanese population.
Katsuyoshi Sugimoto, Tsukasa Uno, Hiroshi Yamazaki, Tomonori Tateishi. Br J Clin Pharmacol 2008
89
8

The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults.
Carlo A Fallone, Naoki Chiba, Sander Veldhuyzen van Zanten, Lori Fischbach, Javier P Gisbert, Richard H Hunt, Nicola L Jones, Craig Render, Grigorios I Leontiadis, Paul Moayyedi,[...]. Gastroenterology 2016
356
8

Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori.
T Furuta, N Shirai, M Kodaira, M Sugimoto, A Nogaki, S Kuriyama, M Iwaizumi, M Yamade, I Terakawa, K Ohashi,[...]. Clin Pharmacol Ther 2007
124
8

Pharmacologic aspects of eradication therapy for Helicobacter pylori Infection.
Takahisa Furuta, David Y Graham. Gastroenterol Clin North Am 2010
67
8

Update on the pharmacogenomics of proton pump inhibitors.
Krisztina Hagymási, Katalin Müllner, László Herszényi, Zsolt Tulassay. Pharmacogenomics 2011
48
8

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing.
K A Birdwell, B Decker, J M Barbarino, J F Peterson, C M Stein, W Sadee, D Wang, A A Vinks, Y He, J J Swen,[...]. Clin Pharmacol Ther 2015
281
8

Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers.
Henry M Dunnenberger, Kristine R Crews, James M Hoffman, Kelly E Caudle, Ulrich Broeckel, Scott C Howard, Robert J Hunkler, Teri E Klein, William E Evans, Mary V Relling. Annu Rev Pharmacol Toxicol 2015
262
8

Pharmacogenomics knowledge for personalized medicine.
M Whirl-Carrillo, E M McDonagh, J M Hebert, L Gong, K Sangkuhl, C F Thorn, R B Altman, T E Klein. Clin Pharmacol Ther 2012
956
8

Effect of CYP2C19*17 gene variant on Helicobacter pylori eradication in peptic ulcer patients.
Mateusz Kurzawski, Barbara Gawrońska-Szklarz, Joanna Wrześniewska, Andrzej Siuda, Teresa Starzyńska, Marek Droździk. Eur J Clin Pharmacol 2006
79
8

CYP2C19 polymorphism and proton pump inhibitors.
Ulrich Klotz, Matthias Schwab, Gerhard Treiber. Basic Clin Pharmacol Toxicol 2004
129
8

CYP2C19 and STAT6 Variants Influence the Outcome of Proton Pump Inhibitor Therapy in Pediatric Eosinophilic Esophagitis.
Edward B Mougey, Andre Williams, Ashlan J Kunz Coyne, Carolina Gutiérrez-Junquera, Sonia Fernández-Fernández, Maria Luz Cilleruelo, Ana Rayo, Luis Echeverría, Enriqueta Román, Carmen González Lois,[...]. J Pediatr Gastroenterol Nutr 2019
12
33

Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis.
James K Y Hooi, Wan Ying Lai, Wee Khoon Ng, Michael M Y Suen, Fox E Underwood, Divine Tanyingoh, Peter Malfertheiner, David Y Graham, Vincent W S Wong, Justin C Y Wu,[...]. Gastroenterology 2017
800
8

Association of CYP2C19 polymorphisms and lansoprazole-associated respiratory adverse effects in children.
John J Lima, Jason E Lang, Edward B Mougey, Kathryn B Blake, Yan Gong, Janet T Holbrook, Robert A Wise, W G Teague. J Pediatr 2013
26
11

Single-dose pharmacokinetics of oral and intravenous pantoprazole in children and adolescents.
Gregory L Kearns, Jeffrey Blumer, Stephen Schexnayder, Laura P James, Kim G Adcock, Michael D Reed, James F Daniel, Andrea Gaedigk, Jeffrey Paul. J Clin Pharmacol 2008
28
10


Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH.
N Shirai, T Furuta, Y Moriyama, H Okochi, K Kobayashi, M Takashima, F Xiao, K Kosuge, K Nakagawa, H Hanai,[...]. Aliment Pharmacol Ther 2001
179
6

Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers.
R Michael Baldwin, Staffan Ohlsson, Rasmus Steen Pedersen, Jessica Mwinyi, Magnus Ingelman-Sundberg, Erik Eliasson, Leif Bertilsson. Br J Clin Pharmacol 2008
112
6

Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17.
Alain Li-Wan-Po, Thierry Girard, Peter Farndon, Candy Cooley, James Lithgow. Br J Clin Pharmacol 2010
162
6

Phenotype-genotype analysis of CYP2C19 in Colombian mestizo individuals.
Carlos Isaza, Julieta Henao, José H Isaza Martínez, Juan C Sepúlveda Arias, Leonardo Beltrán. BMC Clin Pharmacol 2007
28
10

Effects of CYP2C19 Genetic Polymorphisms on PK/PD Responses of Omeprazole in Korean Healthy Volunteers.
Sunny Park, Yang Jin Hyun, Yu Ran Kim, Ju Hyun Lee, Sunae Ryu, Jeong Mi Kim, Woo Yong Oh, Han Sung Na, Jong Gu Lee, Doo Won Seo,[...]. J Korean Med Sci 2017
11
27

Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism.
B-S Sheu, A-W Kao, H-C Cheng, S-F Hunag, T-W Chen, C-C Lu, J-J Wu. Aliment Pharmacol Ther 2005
53
6

CYP2C19 polymorphism has no influence on rabeprazole-based hybrid therapy for Helicobacter pylori eradication.
Tsung-Jung Lin, Hsi-Chang Lee, Chih-Lin Lin, Chung-Kwe Wang, Kuan-Yang Chen, Deng-Chyang Wu. World J Clin Cases 2018
4
75


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.